A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This early-phase study tests the safety and early effectiveness of a new drug called IMV101 — given alone or with other treatments — in adults with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma, a type of blood cancer that has stopped responding to prior therapies. **You may be eligible if...** - You are 18 or older with confirmed B-cell non-Hodgkin lymphoma (such as DLBCL, follicular lymphoma, or mantle cell lymphoma) that has returned or is no longer responding to treatment - You have received at least two prior treatment regimens, or relapsed after a stem cell transplant - Your cancer tests positive for the CD19 protein - You have at least one measurable tumor lesion - Your heart, liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - Your lymphoma has spread to the brain or spinal fluid - You have recently had an organ transplant or stem cell transplant - You are pregnant or breastfeeding - You have active HIV, hepatitis B, hepatitis C, or other serious infections - You have severe heart disease or uncontrolled high blood pressure - You have used immunosuppressive medications recently Talk to your doctor to see if this trial is right for you.